|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The epigenetics market was valued is projected to register a CAGR of 16.1% during the forecast period.
Covid has significantly impacted the epigenetics market growth due to the importance of epigenetics in the COVID-19 research. For instance, according to the study published in · Clinical Epigenetics, titled 'The epigenetic implication in coronavirus infection and therapy' in October 2020, epigenetic alterations might play an essential role in the onset of coronavirus disease complications. Although numerous treatment options are being investigated, further research is urgently needed to discover a viable vaccine or safer chemotherapeutic medications, including epigenetic therapies, to combat this viral pandemic and create pre-and post-exposure COVID-19 prophylaxis. This will therefore lead to increased adoption of epigenetics in the discovery of therapies for COVID-19 infection, thereby expected to drive the market growth over the forecast period.
The factors such as the rising prevalence of cancers, rise in funding in research and development in healthcare, rising applicatoins of non oncological applications of epigenetics, among others are expected to drive the growth of the market studied over the forecast period.
As per Globocan 2020, there were 19, 292, 789 new cancer cases with different types and 9,958,133 deaths due to cancers reported in 2020 worldwide. This worldwide and extensive threat of cancer remains a major driver for the development of new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.
Resistance of cancers to the treatment is a major obstacle. However, epigenetic drugs, on their own or in combination with other drugs, can be a viable alternative. The epigenetic drug used in laboratory study stops the ability of cancer cells to hide from the immune system and makes the tumor vulnerable. Hence, the increasing prevalence of cancer is expected to augment the growth of the epigenetics market.
In addition, rising healthcare research and development expenditure across the globe is further expected to drive the growth of this market over the forecast period. For instance, according to the World Health Organization in December 2021, the gross domestic research and development expenditure on health (health GERD) as a % of gross domestic product (GDP) in high income countries in 0.21% and for upper middle and low income countries, it is 0.02%. Such a huge investments in the healthcare research and development will drive the market growth due to adoption of epegenetics in research.
On the other hand, high cost of epigenetic instruments, dreath of skilled professionals in epigenetic research is expected to hamper the market studied.
Scope of the Report
As per the scope of this report, epigenetics, in simple terms, refers to the study of genetic effects that are not entirely encoded by the DNA sequence of an organism. Epigenetics mainly deals with gene expression. Epigenetics also refers to changes in the genome, in terms of functionality, which do not involve the change in the nucleotide sequence. The DNA methylation or histone modification is a type of mechanism that causes epigenetic changes. The Epigenetics Market is segmented by Product (Instruments, Kits and Reagents, Others), Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases), Technology ( Methylation, Acetylation, Phosphorylation, Other Technologies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
|Reagents & Kits|
Key Market Trends
DNA Methylation is Expected to Hold a Major Share over the Forecast Period
DNA Methylation segment is expected to hold a major share in the market studied over the forecast period. DNA methylation dominated the epigenetics market, as it is the covalent addition of a methyl group in cytosine ring, which leads to the inhibition of transcription. Sensitive bisulfite modification, followed by PCR, is called methylation-sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods, such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI - TOF MS, are also useful for DNA methylation. The advancements in technologies are increasingly enabling the assessment of locus-specific DNA methylation on a genome-wide scale, thereby driving market growth.
Fundraising by the DNA methylation start-up companies is expected to drive the market growth further. For instance, in June 2020, Base Genomics, an epigenetics firm, has emerged from stealth with a team of outstanding scientists and an oversubscribed seed investment round of USD 11 million USD (GBP 9 million) to further its DNA methylation technology development. Oxford Sciences Innovation led the investment round, which included included investors with experience in genomics and cancer. This will lead to increased research on DNA methylation, which will further lead to adopiton of reagents and kits, and instruments for DNA methylation, driving the market growth.
In addition, in February 2021, Twist Bioscience Corporation has launched the Twist NGS Methylation Detection System, an end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome. This will further lead to increased adoption of DNA methylation to study the human genome for research and develop novel therapies, thereby expected to drive this segment growth.
Therefore, owing to the above mentioned factors, this segment is expected to drive over the forecast period.
To understand key trends, Download Sample Report
North America Holds a Major Share in the Epigenetics Market
The factors owing to the growth include rapid developments in healthcare infrastructure, the presence of major players in the region, huge investments made in research and development, rising prevalence of cancers, among others. With increasing investments being made in the research and development of products by industries, an increase in the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines, are produced industrially. There is also growing demand for the development of cancer therapies in the United States, and a lot of investments are made in the understanding of cancer genomics, thereby expected to drive the growth of this market in North America. For instance, according to the United States National Institute of Health in December 2021, the funding for cancer genomics was USD 1,098 million in 2020 and the funding is expected to reach USD 1,152 million in the year 2022. The rise in funding in the United States on cancer genomics will lead to increased adoption of epigenetics in research, thereby expected to drive the market growth over the forecast period.
In addition, rising prevalence of cancer is a;also boosting the growth of market in the region. For Instance, the American Cancer society (ACS), an estimated of 1,918,030 new cases and 609,360 deaths are expected for the year 2022, in the United States and cancer is the leading cause of death for those above the age of 65 in the United States. This will further drive the growth of market studied due to adoption of epigenetics in cancer research.
Moreover, rising investments by the market players in the United States for the development of epigenetics is further expected to drive the growth of the market studied in this region. For instance, in November 2021, Chroma Medicine, Inc., (Chroma) a new genomic medicine company pioneering epigenetic editing, has launched with USD 125 million in financing to address a wide range of diseases and to become the technology of choice for gene regulation.
Therefore, owing to the above mentioned factors, the market is expected to drive in this region.
To understand geography trends, Download Sample Report
The market for epigenetics is moderately competitive. Major players in the market are focusing on the expansion of their epigenetics portfolio by fundraising and investing huge capital in research and development, through acquisitions of, and collaborations with other companies. The epigenetics market is expected to open up several opportunities for the new entrants and the currently established leading players. Some of the major players in this market include, Abcam PLC, Active Motiff, Hologic Inc (Diagenode Inc.), F. Hoffmann-La Roche Ltd, Illumina Inc., Qiagen NV, among others.
- In February 2022, Zenith Epigenetics Ltd. has reported the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.
- In February 2022, Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, has entered a partnership with Dovetail Genomics demonstrating the value and performance of Dovetail’s proximity ligation-based next-generation sequencing (NGS) library prep solutions on Element’s AVITI System.
Table of Contents
1.1 Study Assumptions and Market Defiinition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Cancer
4.2.2 Increasing Funding for R&D in Healthcare
4.2.3 Rising Epigenetic Applications in Non-oncology Diseases
4.3 Market Restraints
4.3.1 Rising Costs of Instruments
4.3.2 Dearth of Skilled Researchers
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.2 Reagents & Kits
5.2 By Application
5.2.2 Autoimmune Diseases
5.2.3 Metabolic Diseases
5.2.4 CNS/Pain Diseases
5.2.5 Cardiovascular Diseases
5.3 By Technology
5.3.4 Other Technologies
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
5.4.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abcam PLC
6.1.2 Active Motiff
6.1.3 Hologic Inc (Diagenode Inc.)
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Illumina Inc.
6.1.6 Merck & Co. Inc.
6.1.7 Qiagen NV
6.1.8 Thermo Fisher Scientific
6.1.9 Zymo Research Corporation
6.1.10 Perkin Elmer
6.1.11 Bio-Rad Laboratories
6.1.12 New England Biolabs
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Epigenetics Market market is studied from 2019 - 2027.
What is the growth rate of Global Epigenetics Market?
The Global Epigenetics Market is growing at a CAGR of 16.1% over the next 5 years.
Which region has highest growth rate in Global Epigenetics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Epigenetics Market?
North America holds highest share in 2021.
Who are the key players in Global Epigenetics Market?
Abcam PLC, Active Motiff, Illumina Inc., Diagenode Inc., Merck KGaA are the major companies operating in Global Epigenetics Market.